麻豆果冻传媒

Investors

Your browser does not support iframes.

News Release

July 1, 2024

EISAI ANNOUNCES MOVE TO SOLO DEVELOPMENT AND COMMERCIALIZATION OF FARLETUZUMAB ECTERIBULIN (FZEC) ANTIBODY DRUG CONJUGATE (ADC)
Strategic collaboration with Bristol Myers Squibb ended
July 1, 2024

麻豆果冻传媒 Announces Status Relating to Acquisition of Own Shares
Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act
June 28, 2024

鈥淟EQEMBI庐鈥� (Lecanemab) for the Treatment of Alzheimer鈥檚 Disease Launched in China
China is the Third Country to Launch LEQEMBI Following the United States and Japan
June 27, 2024

Position and Policy Regarding Reduction of the Investment Unit of the Company's Shares
June 21, 2024

EISAI CONTINUES CONTRACT FOR FY2024 DEMENTIA EXAMINATION PROJECT BY TOKYO BUNKYO CITY
ACHIEVEMENT OF OUTCOME INDICATORS IN FY2023 PAY FOR SUCCESS CONTRACT

Latest Financial Reports

Consolidated Financial Report for Consolidated Annual Financial Report for Fiscal 2023

May 15, 2024

Consolidated Financial Report
May 15, 2024

Reference Data
May 15, 2024

Financial Results Presentation

Latest Financial Reports

Financial Information

Latest Presentations

Electronic Public Notice

No corporate bonds have been issued at present.